

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

O INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

MAY 18 2005

(use as many sheets as necessary)

Application Number	10/632,706
Filing Date	August 1, 2003
First Named Inventor	James D. Marks
Group Art Unit	1645
Examiner Name	Minfield
Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
M	1.	4,689,299		Insel et al.	08/25/1987	
	2.	5,306,730		Nagai et al.	04/26/1994	
	3.	5,807,741		Brown et al.	9/15/1998	
	4.	5,919,665		Williams	07/06/1999	
	5.	5,932,449		Emanuel et al.	8/3/1999	
	6.	6,331,402		Nussbaum et al.	12/18/2001	
	7.	6,416,947		Balasubramanian et al.	07/09/2002	
	8.	6,495,143		Lee et al.	12/17/2002	
	9.	6,667,158		Bavari et al.	12/23/2003	
M	10.	6,841,156		Aoki et al.	01/11/2005	
M	11.	2002/0155114		Marks	10/24/2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appeal	T
		Office	Number	Kind Code (if known)				
M	12.	WO	00/69891		Dept of the Army	11/23/2000		
M	13.	WO	00/69895		Dept of the Army	11/23/2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
M	14.	Amersdorfer et al. (1997) <i>Infect. Immun.</i> , 65: 3743-3752	
M	15.	Amersdorfer et al. (2002) <i>Vaccine</i> 20: 1640-1648	
M	16.	Arnon (1993) Pp. 477-482 in <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R. Plenum, New York	
M	17.	Arnon et al. (2001) <i>J. Am. Med. Assoc.</i> 285: 1059-1070	

Examiner Signature	<i>JM Minfield</i>	Date Considered	12-13-05
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/632,706
(use as many sheets as necessary)		Filing Date	August 1, 2003
		First Named Inventor	James D. Marks
		Group Art Unit	1645
		Examiner Name	MMINNFIELD
		Attorney Docket Number	407T-895120US
		Date Submitted	May 16, 2005

18.	Atassi (1996) <i>J. Protein Chem.</i> , 15: 691-699
19.	Atassi (1996) <i>J. Protein Chem.</i> , 15: 691-699
20.	Black and Gunn. (1980) <i>Am. J. Med.</i> , 69: 567-570
21.	Black, <i>et al.</i> (1980) <i>Am. J. Med.</i> , 69:567-570
22.	Black, <i>et al.</i> (1986) <i>J. Cell Biol.</i> , 103:521-534
23.	Bowmer (1963) <i>Bull. W. H. O.</i> 29: 701-709
24.	Byrne and Smith (2000) <i>Biochimie</i> 82: 955-966
25.	Chen <i>et al.</i> (1997) <i>Infect. Immun.</i> 65(5): 1626-1630
26.	Chen <i>et al.</i> (1998) <i>Infect. Immun.</i> , 66: 2420-2425
27.	Colcher <i>et al.</i> (1990) <i>J. Natl. Cancer Inst.</i> 82: 1191-1197
28.	Daniels-Holgate <i>et al.</i> (1996) <i>J. Neurosci. Res.</i> 44:263-271
29.	Demarchi, <i>et al.</i> (1958) <i>Bull. Acad. Nat. Med.</i> , 142: 580-582
30.	Dolly <i>et al.</i> (1984) <i>Nature (London)</i> 307: 457-460
31.	Emanuel <i>et al.</i> (1996) <i>J. Immunol. Meth.</i> , 193: 189-197
32.	Fitzsimmons <i>et al.</i> (2000) <i>Vaccine</i> 19: 114-121
33.	Foote and Milstein (1991) <i>Nature</i> , 352:530-532
34.	Foote, <i>et al.</i> (1991) <i>Nature</i> 352: 530-532
35.	Fotinou <i>et al.</i> (2001) <i>J. Biol. Chem.</i> 276: 32274-32281
36.	Franz <i>et al.</i> (1993) Pp. 473-476 in <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R. Plenum, New York
37.	Gibson <i>et al.</i> (1988) <i>J. Appl. Bacteriol.</i> , 64: 285-291
38.	Gill (1982) <i>Microbiol. Rev.</i> 46: 86-94
39.	Hallis <i>et al.</i> (1993) Pp. 433-436 In: <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R., Plenum, New York
40.	Hathaway, <i>et al.</i> (1984) <i>J. Infect. Dis.</i> 150:407-412

Examiner Signature	MMINNFIELD	Date Considered	12-13-05
-----------------------	------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/632,706
		Filing Date	August 1, 2003
		First Named Inventor	James D. Marks
		Group Art Unit	1645 1645
		Examiner Name	Minnifield MINNIFIELD
		Attorney Docket Number	407T-895120US
		Date Submitted	May 16, 2005

41.	Hatheway (1995) <i>Curr. Top. Microbio. Immunol.</i> , 195: 55-75
42.	Hatheway and Dang (1994) Pp. 93-107 In: <i>Therapy with Botulinum Toxin</i> , ed. Jankovic, J., Dekker, New York
43.	Hatheway <i>et al.</i> (1984) <i>J. Infect. Dis.</i> , 150: 407-412
44.	Hibbs <i>et al.</i> (1996) <i>Clin. Infect. Dis.</i> , 23: 337-340
45.	Hildebrand, et al. (1961) <i>Proc. Soc. Exp. Biol. Med.</i> 107:284-289
46.	Huston, et al.,(1996) <i>J. Nucl. Med.</i> 40: 320
47.	Koriazova and Montal (2003) <i>Nat. Struct. Biol.</i> , 10: 13-18
48.	Kozaki <i>et al.</i> (1986) <i>Infect. Immun.</i> , 52: 786-791
49.	Kozaki et al. (1995) <i>Microbiol. Immunol.</i> , 39: 767-774
50.	Kozaki <i>et al.</i> (1998) <i>Infect. Immun.</i> , 66: 4811-4816
51.	Lacy and Stevens (1999) <i>J. Mol. Biol.</i> 291: 1091-1104
52.	Lacy et al. (1998) <i>Nat. Struct. Biol.</i> 5: 898-902
53.	Lang, et al. (1993) <i>J. Immunol.</i> 151: 466-473
54.	Mahant et al. (2000) <i>J. Clin. Neurosci.</i> 7: 389-394
55.	Middlebrook and Franz (1997) <i>Botulinum Toxins</i> , chapter 33. In F.R. Sidell, E.T. Takafuji, D.R. Franz (eds.), <i>Medical Aspects of Chemical and Biological Warfare</i> . TMM publications, Washington, D.C.
56.	Middlebrook, et al. (1995) <i>Curr. Top. Microbiol. Immunol.</i> 195:89-122
57.	Montecucco (1986) <i>Trends Biochem. Sci.</i> 11:314-317
58.	Montecucco and Schiavo (1995) <i>Q. Rev. Biophys.</i> 28: 423-472
59.	Montero-Julian <i>et al.</i> (1995) <i>Blood</i> 85: 917-924
60.	Mullaney <i>et al.</i> (2001) <i>Infect. Immun.</i> 69: 6511-6514
61.	Nowakowski <i>et al.</i> (2002) <i>Proc. Natl. Acad. Sci. U S A</i> , 99: 11346-11350
62.	Oguma <i>et al.</i> (1990) <i>Lancet</i> 336: 1449-1450

Examiner Signature	<i>J. M. Minnifield</i>	Date Considered	12-13-05
-----------------------	-------------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/632,706
(use as many sheets as necessary)		Filing Date	August 1, 2003
		First Named Inventor	James D. Marks
		Group Art Unit	1645
		Examiner Name	Minnifield
		Attorney Docket Number	407T-895120US
		Date Submitted	May 16, 2005

MM	63.	Pless et al. (2001) <i>Infect. Immun.</i> 69: 570-574	
MM	64.	Reichert (2001) <i>Nat. Biotechnol.</i> 19: 819-822	
MM	65.	Schengrund (1999) <i>J Toxicol Toxin Rev.</i> , 18: 35-44	
MM	66.	Schiavo et al. (1992) <i>Nature (London)</i> 359: 832-835	
MM	67.	Schiavo et al. (1993) <i>J. Biol. Chem.</i> 268: 23784-23787	
MM	68.	Schier et al. (1995) <i>Immunotechnology</i> , 1: 73-81	
MM	69.	Siegel (1988) <i>J. Clin. Microbiol.</i> 26: 2351-2356	
MM	70.	Simpson (1980) <i>J. Pharmacol. Exp. Ther.</i> 212: 16-21	
MM	71.	Sonnabend et al. (1981) <i>J. Infect. Dis.</i> , 143: 22-27	
MM	72.	Tacket et al. <i>Am. J. Med.</i> , 76: 794-798	
MM	73.	Volk et al. (1984) <i>Infect. Immun.</i> 45: 604-609	
MM	74.	Williams et al. (1983) <i>Eur. J. Biochem.</i> , 131: 437-445	
MM	75.	Zwick et al. (2001) <i>J. Virol.</i> 75: 12198-12208	

Examiner Signature	MM Minnifield	Date Considered	12-13-05
-----------------------	---------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>		Application Number	10/632,706
		Filing Date	August 1, 2003
		First Named Inventor	James D. Marks
		Group Art Unit	1645
		Examiner Name	MINNIFIELD
		Attorney Docket Number	407T-895120US
		Date Submitted	October 7, 2005



U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
1	2004/0265935 A1			Atassi	12/30/2004
2	2004/0175385 A1			Marks et al.	09/09/2004

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T	
3	HALL (2004) Journal of Immunological Methods 288, pp. 55-60						
4	OSHIIMA (1997) Molecular Immunology Vol. 34, No. 14, pp. 1031-1040						

Examiner Signature	<i>NM Minnifield</i>	Date Considered	12/13/05
--------------------	----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.